Long COVID Atlas
Text Theme
Note

Education, not medical advice. Do not start, stop, or change any medication or supplement without your own clinician, who knows your history and other medicines.

Treatment · Repurposed drug

Low-dose naltrexone (LDN)

A well-known drug, at a tiny fraction of its usual dose, that may quiet the inflammation behind long COVID fatigue. Small studies are encouraging and a trial is underway, but LDN is still unproven, used off-label.

Short version: low-dose naltrexone may calm inflammatory signaling and ease fatigue in long COVID. Promising in small uncontrolled studies, generally well tolerated, but not yet proven in a randomized trial.

A familiar drug at a fraction of the dose

At low doses (around 1 to 4.5 mg), naltrexone behaves differently than at its standard dose, appearing to calm inflammatory signaling and microglia via TLR4, which is why it is tried for fatigue and pain in long COVID and ME/CFS.1

Why thinking feels slow bloodstream: lasting inflammation, clotting signals blood-brain barrier, now leaky microglia (brain immune cells) switch on brain fog: slow recall, poor focus,word-finding trouble
Brain fog is not laziness or anxiety. Lasting inflammation in the blood, together with a brain barrier that has become leaky, lets inflammatory signals reach brain tissue and switches on the brain's own immune cells, the microglia. That low-grade neuroinflammation is what slows recall, focus, and word-finding.

What the evidence says

Several small before-and-after studies report improved energy, concentration, pain, and sleep, and a pooled analysis found a moderate effect on fatigue. But there is no completed randomized controlled trial yet; one is underway.1, 2, 3

promising, uncontrolled RCT pending

How it is used

It is off-label, generally well tolerated, and usually started very low and titrated. Vivid dreams and early sleep disturbance are the common, transient side effects. The honest status is promising but unproven.

What we don't know

Honest about the edges of the evidence. These are open questions, not settled answers.

  • Whether LDN beats placebo in a randomized trial.
  • Who responds and at what dose.
  • How it works at the molecular level.
  • How durable any benefit is.

References

Every reference is free to read in full.

  1. Safety and efficacy of low-dose naltrexone in a long COVID cohort (pre-post study).
  2. Low-dose naltrexone plus NAD for post-COVID fatigue (pilot).
  3. Low-dose naltrexone for post-COVID fatigue syndrome: randomised trial protocol (BMJ Open 2024).

Associated topics

SymptomChronic fatiguetreatsMechanismNeuroinflammation / microglial activationa treatment triedMechanismMast cell activationa treatment tried